Celecoxib in patients with asthma and aspirin intolerance [5]

New England Journal of Medicine

Volumn 344, Issue 2, 2001, Pages 142-

  Dahlén, Barbro ^a   Szczeklik, Andrew ^b   Murray, John J ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

ADULT; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG MECHANISM; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; MALE; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; BRONCHIAL SPASM; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 0035843257     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200101113440215     Document Type: Letter

References (3)

1. Aspirin-induced asthma: Advances in pathogenesis and management
2. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
3. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics